^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT amplification

    i
    Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    2years
    A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=282, Completed, Deciphera Pharmaceuticals LLC | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation • KIT amplification
    |
    Qinlock (ripretinib)
    over2years
    A single-arm, phase II clinical study of imatinib mesylate/toripalimab combo in patients (pts) with advanced melanoma harboring c-Kit mutation or amplification (ESMO 2022)
    Conclusions Imatinib mesylate/toripalimab combo was effective and well-tolerated in pts with advanced melanoma harboring c-kit aberrations. Longer follow-up and further patient recruitment are in need.
    Clinical • P2 data • PD(L)-1 Biomarker • IO biomarker
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT amplification
    |
    imatinib • Loqtorzi (toripalimab-tpzi)
    over3years
    A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=320, Active, not recruiting, Deciphera Pharmaceuticals LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation • KIT amplification
    |
    Qinlock (ripretinib)
    almost4years
    Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov)
    P2, N=81, Completed, Eastern Cooperative Oncology Group | Active, not recruiting --> Completed
    Clinical • Trial completion
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT positive • KIT amplification
    |
    dasatinib
    4years
    A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies (clinicaltrials.gov)
    P1, N=320, Recruiting, Deciphera Pharmaceuticals LLC | Trial completion date: Feb 2021 --> Jun 2022 | Trial primary completion date: Feb 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    KIT mutation • PDGFRA mutation • KIT amplification
    |
    Qinlock (ripretinib)
    4years
    Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery (clinicaltrials.gov)
    P2, N=81, Active, not recruiting, Eastern Cooperative Oncology Group | Trial completion date: Aug 2020 --> Dec 2020
    Clinical • Trial completion date
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase)
    |
    KIT mutation • KIT positive • KIT amplification
    |
    dasatinib